| | | | | | | | | | | | | | | | |
| | |
 | Issue Date FY: 2025 ( Subtotal = $0 ) |
| | 2025 | 2022 | ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (ERASMUS MC) | DR. MOLEWATERPLEIN 40 | ROTTERDAM | | | | NLD | R21CA274064 | Investigating PROTAC-mediated antigen degradation as a novel strategy to enhance cytotoxic T-cell responses against cancer in vivo. | 000 | 1 | NIH | 11/6/2024 | $0 |
|
| Issue Date FY: 2024 ( Subtotal = $473,525 ) |
| | 2024 | 2024 | ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (ERASMUS MC) | DR. MOLEWATERPLEIN 40 | ROTTERDAM | | | | NLD | R01AI177487 | Unravelling highly pathogenic influenza virus emergence | 000 | 2 | NIH | 7/22/2024 | $473,525 |
|
| Issue Date FY: 2023 ( Subtotal = $1,074,368 ) |
| | 2023 | 2023 | ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (ERASMUS MC) | DR. MOLEWATERPLEIN 40 | ROTTERDAM | | | | NLD | R01AI147330 | Novel mechanisms contributing to failure of dolutegravir-containing cART in clinical practice | 002 | 5 | NIH | 9/7/2023 | $59,423 |
| | 2023 | 2023 | ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (ERASMUS MC) | DR. MOLEWATERPLEIN 40 | ROTTERDAM | | | | NLD | R01AI147330 | Novel mechanisms contributing to failure of dolutegravir-containing cART in clinical practice | 001 | 5 | NIH | 7/20/2023 | $616,892 |
| | 2023 | 2023 | ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (ERASMUS MC) | DR. MOLEWATERPLEIN 40 | ROTTERDAM | | | | NLD | R01AI147330 | Novel mechanisms contributing to failure of dolutegravir-containing cART in clinical practice | 000 | 4 | NIH | 6/15/2023 | $13,388 |
| | 2023 | 2023 | ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (ERASMUS MC) | DR. MOLEWATERPLEIN 40 | ROTTERDAM | | | | NLD | R01AI177487 | Unravelling highly pathogenic influenza virus emergence | 000 | 1 | NIH | 7/31/2023 | $384,665 |
|
| Issue Date FY: 2022 ( Subtotal = $884,002 ) |
| | 2022 | 2022 | ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (ERASMUS MC) | DR. MOLEWATERPLEIN 40 | ROTTERDAM | ZUID-HOLLAND | | | NLD | R21CA274064 | Investigating PROTAC-mediated antigen degradation as a novel strategy to enhance cytotoxic T-cell responses against cancer in vivo. | 000 | 1 | NIH | 9/8/2022 | $277,686 |
| | 2022 | 2022 | ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (ERASMUS MC) | DR. MOLEWATERPLEIN 40 | ROTTERDAM | ZUID-HOLLAND | | | NLD | R01AI147330 | Novel mechanisms contributing to failure of dolutegravir-containing cART in clinical practice | 000 | 4 | NIH | 8/31/2022 | $606,316 |
|
| Issue Date FY: 2021 ( Subtotal = $614,205 ) |
| | 2021 | 2021 | ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (ERASMUS MC) | DR. MOLEWATERPLEIN 40 | ROTTERDAM | ZUID-HOLLAND | | | NLD | R01AI147330 | Novel mechanisms contributing to failure of dolutegravir-containing cART in clinical practice | 000 | 3 | NIH | 9/14/2021 | $614,205 |
| | 2021 | 2021 | ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM (ERASMUS MC) | DR. MOLEWATERPLEIN 40 | ROTTERDAM | ZUID-HOLLAND | | | NLD | R01AI147330 | Novel mechanisms contributing to failure of dolutegravir-containing cART in clinical practice | 001 | 3 | NIH | 9/17/2021 | $0 |
|
| Issue Date FY: 2020 ( Subtotal = $613,626 ) |
| | 2020 | 2020 | ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM | 'S-GRAVENDIJKWAL 230 | ROTTERDAM | ZUID-HOLLAND | 3015 CE | | NLD | R01AI147330 | Novel mechanisms contributing to failure of dolutegravir-containing cART in clinical practice | 000 | 2 | NIH | 7/23/2020 | $613,626 |
|
| Issue Date FY: 2019 ( Subtotal = $628,572 ) |
| | 2019 | 2019 | ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM | 'S-GRAVENDIJKWAL 230 | ROTTERDAM | ZUID-HOLLAND | 3015 CE | | NLD | R01AI147330 | Novel mechanisms contributing to failure of dolutegravir-containing cART in clinical practice | 000 | 1 | NIH | 8/20/2019 | $628,572 |
|
| Issue Date FY: 2018 ( Subtotal = -$136,692 ) |
| | 2018 | 2013 | ERASMUS UNIVERSITAIR MEDISCH CENTRUM ROTTERDAM | 'S-GRAVENDIJKWAL 230 | ROTTERDAM | ZUID-HOLLAND | 3015 CE | | NLD | R37DK054077 | Characterization of the first HSCs during mouse ontogeny | 000 | 16 | NIH | 9/30/2018 | -$136,692 |
|
| Issue Date FY: 2014 ( Subtotal = -$136,693 ) |
| | 2014 | 2013 | ERASMUS MC | POST OFFICE BOX 1738 | ROTTERDAM | | | | NLD | R37DK054077 | Characterization of the first HSCs during mouse ontogeny | 000 | 16 | NIH | 12/4/2013 | -$136,693 |
|
| Issue Date FY: 2013 ( Subtotal = $136,692 ) |
| | 2013 | 2013 | ERASMUS MC | POST OFFICE BOX 1738 | ROTTERDAM | | | | NLD | R37DK054077 | Characterization of the first HSCs during mouse ontogeny | 001 | 16 | NIH | 12/4/2013 | -$136,693 |
| | 2013 | 2013 | ERASMUS MC | POST OFFICE BOX 1738 | ROTTERDAM | | | | NLD | R37DK054077 | Characterization of the first HSCs during mouse ontogeny | 000 | 16 | NIH | 3/19/2013 | $273,385 |
|
| Issue Date FY: 2012 ( Subtotal = $303,760 ) |
| | 2012 | 2012 | ERASMUS MC | POST OFFICE BOX 1738 | ROTTERDAM | | | | NLD | R37DK054077 | Characterization of the first HSCs during mouse ontogeny | 000 | 15 | NIH | 3/29/2012 | $303,760 |
|
| Issue Date FY: 2011 ( Subtotal = $291,846 ) |
| | 2011 | 2011 | ERASMUS MC | POST OFFICE BOX 1738 | ROTTERDAM | | | | NLD | R37DK054077 | Characterization of the first HSCs during mouse ontogeny | 000 | 14 | NIH | 4/18/2011 | $291,846 |
| | 2011 | 2011 | ERASMUS MC | POST OFFICE BOX 1738 | ROTTERDAM | | 00000 | | NLD | R37DK054077 | Characterization of the first HSCs during mouse ontogeny | 001 | 14 | NIH | 7/1/2011 | $0 |
|
| Issue Date FY: 2010 ( Subtotal = $245,662 ) |
| | 2010 | 2010 | ERASMUS MC | POST OFFICE BOX 1738 | ROTTERDAM | | | | NLD | R37DK054077 | Characterization of the first HSCs during mouse ontogeny | 000 | 13 | NIH | 4/8/2010 | $245,662 |
|
| Issue Date FY: 2009 ( Subtotal = $243,021 ) |
| | 2009 | 2009 | ERASMUS MC | POST OFFICE BOX 1738 | ROTTERDAM | | - | | NLD | R37DK054077 | Characterization of the first HSCs during mouse ontogeny | 000 | 12 | NIH | 7/15/2009 | $243,021 |
|
| Issue Date FY: 2007 ( Subtotal = $654,784 ) |
| | 2007 | 2007 | ERASMUS MC | POST OFFICE BOX 1738 | ROTTERDAM | | 00000 | | NLD | R01NS042691 | CLINICAL TRIAL DESIGN AND ANALYSIS IN TRAUMATIC BRAIN INJURY | 000 | 4 | NIH | 4/13/2007 | $416,857 |
| | 2007 | 2007 | ERASMUS MC | POST OFFICE BOX 1738 | ROTTERDAM | | 00000 | | NLD | R37DK054077 | Characterization of the first HSCs during mouse ontogeny | 000 | 10 | NIH | 5/9/2007 | $237,927 |
|
| Issue Date FY: 2006 ( Subtotal = $418,160 ) |
| | 2006 | 2006 | ERASMUS MC | POST OFFICE BOX 1738 | ROTTERDAM | | 00000 | | NLD | R37DK054077 | Characterization of the first HSCs during mouse ontogeny | 000 | 9 | NIH | 7/18/2006 | $207,236 |
| | 2006 | 2006 | ERASMUS MC | POST OFFICE BOX 1738 | ROTTERDAM | | 00000 | | NLD | R01HL073455 | MOLECULAR BASIS OF HUMAN GAMMA-GLOBIN GENE ACTIVATION. | 000 | 4 | NIH | 8/22/2006 | $210,924 |
|
| Issue Date FY: 2005 ( Subtotal = $837,083 ) |
| | 2005 | 2005 | ERASMUS MC | POST OFFICE BOX 1738 | ROTTERDAM | | 00000 | | NLD | R01HL073455 | MOLECULAR BASIS OF HUMAN GAMMA-GLOBIN GENE ACTIVATION. | 000 | 3 | NIH | 9/9/2005 | $216,000 |
| | 2005 | 2005 | ERASMUS MC | POST OFFICE BOX 1738 | ROTTERDAM | | 00000 | | NLD | R01DK054077 | CHARACTERIZATION OF THE FIRST HSCS DURING MOUSE ONTOGENY | 000 | 8 | NIH | 5/13/2005 | $148,729 |
| | 2005 | 2005 | ERASMUS MC | POST OFFICE BOX 1738 | ROTTERDAM | | 00000 | | NLD | R01NS042691 | CLINICAL TRIAL DESIGN AND ANALYSIS IN TRAUMATIC BRAIN INJURY | 000 | 3 | NIH | 2/10/2005 | $472,354 |
|
| Issue Date FY: 2004 ( Subtotal = $893,842 ) |
| | 2004 | 2004 | ERASMUS MC | POST OFFICE BOX 1738 | ROTTERDAM | | 00000 | | NLD | R01HL073455 | MOLECULAR BASIS OF HUMAN GAMMA-GLOBIN GENE ACTIVATION. | 000 | 2 | NIH | 7/13/2004 | $216,000 |
| | 2004 | 2004 | ERASMUS MC | POST OFFICE BOX 1738 | ROTTERDAM | | 00000 | | NLD | R01NS042691 | CLINICAL TRIAL DESIGN AND ANALYSIS IN TRAUMATIC BRAIN INJURY | 000 | 2 | NIH | 4/1/2004 | $474,148 |
| | 2004 | 2004 | ERASMUS MC | POST OFFICE BOX 1738 | ROTTERDAM | | 00000 | | NLD | U01CA088202 | SURVEILLANCE OF BREAST CANCER TRENDS BIJ MISCAN | 001 | 4 | NIH | 9/21/2004 | $53,449 |
| | 2004 | 2004 | ERASMUS MC | POST OFFICE BOX 1738 | ROTTERDAM | | 00000 | | NLD | R01DK054077 | CHARACTERIZATION OF THE FIRST HSCS DURING MOUSE ONTOGENY | 000 | 7 | NIH | 2/4/2004 | $150,245 |
|
|
